TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9253574

Group type: EXPERIMENTAL
Intervention: Haemodilution alone (Group C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of PGE1-induced hypotension and haemodilution (Group D)
Number of subjects: 40

Group type: COMPARATOR
Intervention: PGE1-induced hypotension alone (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All groups post-surgery
Number of subjects: 40
Study: 8494421

Group type: EXPERIMENTAL
Intervention: University of Wisconsin solution (UWS)
Number of subjects: 39

Group type: COMPARATOR
Intervention: St. Thomas' Hospital solution (STS)
Number of subjects: 39
Study: 31296654

Group type: EXPERIMENTAL
Intervention: Postrandomization events (recurrent stroke, myocardial infarction, major bleeding, serious adverse events) in stroke cohort
Number of subjects: 6047

Group type: EXPERIMENTAL
Intervention: Postrandomization events (recurrent stroke, myocardial infarction, major bleeding, serious adverse events) in TIA cohort
Number of subjects: 6047

Group type: EXPERIMENTAL
Intervention: NIHSS score
Number of subjects: 6047

Group type: EXPERIMENTAL
Intervention: Limb weakness
Number of subjects: 6047

Group type: EXPERIMENTAL
Intervention: Disability at 90 days in stroke patients
Number of subjects: 6047

Group type: EXPERIMENTAL
Intervention: Disability at 90 days in TIA patients
Number of subjects: 6047
Study: 29522355

Group type: EXPERIMENTAL
Intervention: NaNO3 supplementation (1 g/day, n = 13)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose, n = 8)
Number of subjects: 21
Study: 27980499

Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (6 mg∙kg‐1 body mass anhydrous caffeine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (artificial sweetener)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeine supplementation
Number of subjects: 10
Study: 25319951

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg 12 h before PCI, and a further 20 mg 2 h preprocedure)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 159
Study: 22678167

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (DS twice daily)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 212
Study: 19669674

Group type: EXPERIMENTAL
Intervention: Keshet program (experimental group)
Number of subjects: 49

Group type: COMPARATOR
Intervention: No structural intervention (control group)
Number of subjects: 49
Study: 18432390

Group type: COMPARATOR
Intervention: Advertising prewarning (before the episode)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Health warning (after the episode)
Number of subjects: 250

Group type: COMPARATOR
Intervention: No warning (control condition)
Number of subjects: 250
Study: 15732545

Group type: EXPERIMENTAL
Intervention: Material A (Affinis, Coltène/Whaledent)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Material B (control)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Material A
Number of subjects: 130
Study: 12602406

Group type: EXPERIMENTAL
Intervention: Combination of metformin and glucose-lowering sulphonylurea
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulphonylurea alone
Number of subjects: 0
Study: 10561675

Group type: EXPERIMENTAL
Intervention: 100 microg levonorgestrel with 20 microg ethinyl estradiol
Number of subjects: 155

Group type: COMPARATOR
Intervention: Triphasic norethindrone with ethinyl estradiol
Number of subjects: 155
Study: 8763311

Group type: EXPERIMENTAL
Intervention: 10% phenylephrine
Number of subjects: 115

Group type: COMPARATOR
Intervention: 2.5% phenylephrine
Number of subjects: 115
Study: 1832101

Group type: EXPERIMENTAL
Intervention: Electric toothbrush (aided by parent or staff)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Electric toothbrush (unaided)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Manual toothbrush (aided by parent or staff)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Manual toothbrush (unaided)
Number of subjects: 23
Study: 6871054

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 17

Group type: COMPARATOR
Intervention: Alcuronium
Number of subjects: 17
Study: 30052328

Group type: EXPERIMENTAL
Intervention: Alicapistat 400- or 800-mg twice-daily doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Donepezil 10 mg twice daily (active control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alicapistat (various doses)
Number of subjects: 0
Study: 29521283

Group type: EXPERIMENTAL
Intervention: FDAE group (Group E)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 302
Study: 26712571

Group type: EXPERIMENTAL
Intervention: McGrath video laryngoscope
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Number of subjects: 95
Study: 25082956

Group type: EXPERIMENTAL
Intervention: Knee-ankle-foot orthosis equipped with an Ultraflex ankle power unit, used for at least 6 hours every other night for one year.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no knee-ankle-foot orthosis).
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Knee-ankle-foot orthosis wearing time.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Secondary outcome measures (ankle-foot and knee angle in gait, gross motor function).
Number of subjects: 28
Study: 22246217

Group type: EXPERIMENTAL
Intervention: Weight-bearing physical activity (2 sessions of 90 minutes per week for 9 months)
Number of subjects: 59
Study: 19460767

Group type: EXPERIMENTAL
Intervention: ADX10059 250 mg tds
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ADX10059 50 mg tds
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17172351

Group type: EXPERIMENTAL
Intervention: docetaxel 60 mg/m2 and cisplatin 50 mg/m2
Number of subjects: 101

Group type: COMPARATOR
Intervention: paclitaxel 175 mg/m2 and cisplatin 50 mg/m2
Number of subjects: 101
Study: 15367301

Group type: EXPERIMENTAL
Intervention: Neuraxial analgesia (intrathecal and epidural)
Number of subjects: 87
Study: 11592667

Group type: EXPERIMENTAL
Intervention: Partial menu map with visual momentum design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Partial menu map without visual momentum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Command-only representation
Number of subjects: 0
Study: 9480998

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol
Number of subjects: 52

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 52
Study: 7672876

Group type: EXPERIMENTAL
Intervention: Contractubex gel (10% onion extract, 50/U of sodium heparin per 1g of gel, 1% allantoin), applied topically for one year starting 26 days post-operation.
Number of subjects: 45

Group type: COMPARATOR
Intervention: No treatment (control group).
Number of subjects: 45
Study: 2919059

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.1% mouthrinses (rinsed four times daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo mouthrinses
Number of subjects: 30
Study: 31978826

Group type: EXPERIMENTAL
Intervention: Combined high intensity progressive resistance and computerised cognitive training (PRT+CCT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Physical resistance training (PRT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham physical+sham cognitive training (SHAM+SHAM)
Number of subjects: 100
Study: 30579584

Group type: EXPERIMENTAL
Intervention: Care within a medical home
Number of subjects: 202

Group type: COMPARATOR
Intervention: Low socioeconomic status (young caregiver)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Low socioeconomic status (low education)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Delayed language
Number of subjects: 202

Group type: COMPARATOR
Intervention: Degree of prematurity and neonatal clinic follow‐up participation
Number of subjects: 202
Study: 24989482

Group type: EXPERIMENTAL
Intervention: Motivational strategies intervention (IG)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standardized information (CG1)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Routine procedures (CG2)
Number of subjects: 61
Study: 22849770

Group type: EXPERIMENTAL
Intervention: ACT‐178882 (single dose 30 mg in fed state)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT‐178882 (multiple doses 30‐600 mg once daily for 14 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT‐178882 (single doses 10‐1000 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT‐178882 (multiple doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACT‐178882 and Enalapril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT‐178882
Number of subjects: 0
Study: 21742303

Group type: EXPERIMENTAL
Intervention: Low-fluence photodynamic therapy (PDT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravitreal injections of ranibizumab
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 16
Study: 19926780

Group type: EXPERIMENTAL
Intervention: Feedback training mode
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational training mode
Number of subjects: 0
Study: 16826467

Group type: EXPERIMENTAL
Intervention: Intervention group (IG) - invitation, counselling, application support; 69% participated in a 3 week in-patient multidisciplinary rehabilitation program
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (KG) - usual care; 20% participated in a 3 week in-patient multidisciplinary rehabilitation program
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Intervention group (IG)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (KG)
Number of subjects: 230
Study: 14695940

Group type: EXPERIMENTAL
Intervention: Short term administration of a nutraceutical formulation based on coenzyme Q10, vitamin E, selenium, methionine, and phospholipids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of city clerks
Number of subjects: 0
Study: 10649623

Group type: EXPERIMENTAL
Intervention: Pnc conjugate vaccine (1, 3, or 10 micrograms of PSs conjugated to diphtheria or tetanus toxoid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pnc conjugate vaccine
Number of subjects: 0
Study: 8783392

Group type: EXPERIMENTAL
Intervention: Regular nicotine cigarette (0.7 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Denicotinised cigarette (0.1 mg)
Number of subjects: 0
Study: 1534287

Group type: EXPERIMENTAL
Intervention: Intravenous tissue-type plasminogen activator (t-PA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 2937411

Group type: EXPERIMENTAL
Intervention: celiprolol hydrochloride (300 mg once daily for 4 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 21
Study: 29453170

Group type: EXPERIMENTAL
Intervention: Stepping with the paretic leg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stepping with the non-paretic leg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stepping speed
Number of subjects: 0
Study: 27636593

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT) on the perilimbal sclera
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional SLT with gonioscopy lens
Number of subjects: 30
Study: 26232049

Group type: EXPERIMENTAL
Intervention: Intravenous IgG administered at replacement dosages
Number of subjects: 0
Study: 23997136

Group type: EXPERIMENTAL
Intervention: Hohmann procedure (50 feet)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Lapidus procedure (51 feet)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Hohmann procedure (subgroup with hypermobility)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Lapidus procedure (subgroup with hypermobility)
Number of subjects: 101
Study: 20556613

Group type: EXPERIMENTAL
Intervention: Regimen B (docetaxel with 150 mg single-dose oral casopitant)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Regimen A (docetaxel without casopitant)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both Regimen A and Regimen B
Number of subjects: 14
Study: 18940393

Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg/d) with pioglitazone (30 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pioglitazone (30 mg/d) + Placebo
Number of subjects: 0
Study: 16801406

Group type: EXPERIMENTAL
Intervention: Telbivudine 200 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telbivudine with lamivudine (100 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telbivudine with adefovir dipivoxil (10 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lamivudine with telbivudine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adefovir dipivoxil with telbivudine
Number of subjects: 0
Study: 12974995

Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo monotherapy
Number of subjects: 468

Group type: COMPARATOR
Intervention: Paroxetine augmentation
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Paroxetine (in patients with lithium levels <=0.8 mequiv./l)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Moclobemide monotherapy
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 468
Study: 10831173

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) infusion of 3.3 mmol/kg lysine hydrochloride over 90 minutes
Number of subjects: 10
Study: 9217380

Group type: EXPERIMENTAL
Intervention: HEPCON HMS system
Number of subjects: 34

Group type: COMPARATOR
Intervention: Classical ACT management
Number of subjects: 34
Study: 7679615

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg b.i.d.)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 2425159

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 29936703

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD) therapy
Number of subjects: 126

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 126
Study: 27278474

Group type: EXPERIMENTAL
Intervention: Recruitment brochure
Number of subjects: 60000

Group type: COMPARATOR
Intervention: Postcard
Number of subjects: 60000

Group type: EXPERIMENTAL
Intervention: Targeted postcard (includes 'Men' in headline)
Number of subjects: 60000

Group type: COMPARATOR
Intervention: Generic postcard
Number of subjects: 60000

Group type: EXPERIMENTAL
Intervention: Targeted postcard (for women)
Number of subjects: 60000

Group type: COMPARATOR
Intervention: Generic postcard (for women)
Number of subjects: 60000
Study: 25014648

Group type: EXPERIMENTAL
Intervention: Fast track rehabilitation protocol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional protocol
Number of subjects: 20
Study: 23174399

Group type: EXPERIMENTAL
Intervention: Epimacular brachytherapy (EMBT)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Ranibizumab monotherapy (control)
Number of subjects: 494
Study: 22025377

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal Control Group
Number of subjects: 28

Group type: COMPARATOR
Intervention: MI-Untrained Group
Number of subjects: 28
Study: 18499008

Group type: EXPERIMENTAL
Intervention: Phaco chop
Number of subjects: 60

Group type: COMPARATOR
Intervention: Divide and conquer
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 16575739

Group type: EXPERIMENTAL
Intervention: Posaconazole (200 mg on day 1, followed by 100 mg/day for 13 days)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Fluconazole (200 mg on day 1, followed by 100 mg/day for 13 days)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 350

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Posaconazole and Fluconazole
Number of subjects: 350
Study: 12676389

Group type: EXPERIMENTAL
Intervention: Intracervical Foley catheter
Number of subjects: 90

Group type: COMPARATOR
Intervention: Prostaglandin E(2) tablets
Number of subjects: 90
Study: 10739742

Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (0.2%, 0.4%)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Trans-retinoic acid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Calcipotriol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vaseline
Number of subjects: 30
Study: 9163863

Group type: EXPERIMENTAL
Intervention: CyA-ME (microemulsion formulation)
Number of subjects: 22

Group type: COMPARATOR
Intervention: CyA-GC (corn oil-based gel capsule)
Number of subjects: 22
Study: 1546124

Group type: EXPERIMENTAL
Intervention: Moclobemide 450 mg/day
Number of subjects: 268

Group type: COMPARATOR
Intervention: Toloxatone 1000 mg/day
Number of subjects: 268
Study: 3096181

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate therapy (variable doses based on initial arterial pH)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no sodium bicarbonate therapy)
Number of subjects: 21
Study: 29109363

Group type: EXPERIMENTAL
Intervention: 0.033 mg/kg/day Norditropin® (somatropin)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 0.066 mg/kg/day Norditropin® (somatropin)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Comparison between 0.033 mg/kg/day and 0.066 mg/kg/day
Number of subjects: 51
Study: 27298411

Group type: EXPERIMENTAL
Intervention: Chemotherapy (epirubicin, cisplatin, and fluorouracil)
Number of subjects: 330
Study: 23831181

Group type: EXPERIMENTAL
Intervention: Stressful life events measured using the Geriatric Life Events Scale (GALES)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Depressive symptoms assessed with the Short - Geriatric Depression Scale (S-GDS)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Stressful life events
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Females and persons with worse health
Number of subjects: 144
Study: 22302518

Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel
Number of subjects: 261

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 261
Study: 20138067

Group type: EXPERIMENTAL
Intervention: Naltrexone (50mg PO)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fat (Naltrexone)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fat (Placebo)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Non-Fat (Placebo)
Number of subjects: 21
Study: 18541949

Group type: EXPERIMENTAL
Intervention: Early delivery and advances in supportive management
Number of subjects: 16252

Group type: EXPERIMENTAL
Intervention: Liver disorders unique to pregnancy
Number of subjects: 16252

Group type: EXPERIMENTAL
Intervention: Preeclampsia, HELLP syndrome, acute fatty liver of pregnancy
Number of subjects: 16252

Group type: EXPERIMENTAL
Intervention: Liver test abnormalities
Number of subjects: 16252
Study: 19242554

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g/day loading dose for 5 days, followed by 4.8 g/day maintenance)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (equivalent number of placebo capsules)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15880338

Group type: EXPERIMENTAL
Intervention: Breathlessness
Number of subjects: 3029

Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 3029
Study: 11716330

Group type: EXPERIMENTAL
Intervention: Nonselective LIMA angiography using a 5 Fr Judkins JL‐3.5 catheter with cuff inflation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Nonselective LIMA angiography using a 5 Fr Judkins JL‐3.5 catheter without cuff inflation
Number of subjects: 110
Study: 9931883

Group type: EXPERIMENTAL
Intervention: Intraperitoneal active charcoal-mitomycin C therapy (MMC‐CH)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: R0 resection with MMC‐CH therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Palliative resection without cytoreductive surgery
Number of subjects: 64
Study: 8072048

Group type: EXPERIMENTAL
Intervention: Experimental acupuncture treatment
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo acupuncture treatment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and placebo)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Self-report outcomes
Number of subjects: 150
Study: 3384243

Group type: EXPERIMENTAL
Intervention: 5F Judkins catheters (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5F Amplatz catheters (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Brachial artery occlusion (Group B)
Number of subjects: 60
Study: 30760751

Group type: EXPERIMENTAL
Intervention: Intranasal administration of oxytocin (OT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29914523

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training with ankle dorsiflexion assistance (Robotic Group, n=9)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham Group (passive AFO, n=10)
Number of subjects: 19
Study: 27798022

Group type: EXPERIMENTAL
Intervention: Parenting Acceptance and Commitment Therapy (PACT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 66
Study: 24589084

Group type: EXPERIMENTAL
Intervention: FEIBA prophylaxis (85 ± 15 U kg(‐1) every other day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: FEIBA prophylaxis
Number of subjects: 36

Group type: COMPARATOR
Intervention: On-demand treatment
Number of subjects: 36
Study: 22123270

Group type: EXPERIMENTAL
Intervention: Nefopam 30 mg tablet (Acupan®)
Number of subjects: 12
Study: 18485252

Group type: EXPERIMENTAL
Intervention: Topical application of pure natural honey during concomitant chemotherapy and radiotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Concomitant chemotherapy and radiotherapy without honey (Control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topical application of pure natural honey
Number of subjects: 40